Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | SLC5A2 | P31639 | 18/20 | 0.64 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31741260 | 1.00 | ATM (0.67) | ATMSLC5A2SLC5A1 | |
| SCHEMBL3805865 | 1.00 | ATM (0.67) | ATMSLC5A2SLC5A1 | |
| SCHEMBL7191502 | 1.00 | ATM (0.67) | ATMSLC5A2SLC5A1 | |
| SCHEMBL3719106 | 1.00 | ATM (0.67) | ATMSLC5A2SLC5A1 | |
| SCHEMBL2191348 | 1.00 | ATM (0.67) | ATMSLC5A2SLC5A1 | |
| SCHEMBL3724838 | 0.99 | ATM (0.65) | ATMSLC5A2SLC5A1 | |
| SCHEMBL3406199 | 0.86 | SLC5A2 (0.49) | ATMSLC5A2SLC5A1 | |
| SCHEMBL2193732 | 0.84 | SLC5A2 (0.47) | ATMSLC5A2SLC5A1 | |
| SCHEMBL6037243 | 0.84 | ATM (0.58) | ATMSLC5A2SLC5A1 | |
| SCHEMBL6232574 | 0.84 | ATM (0.58) | ATMSLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013078392-A1 | METHODS AND COMPOSITIONS INVOLVING INDUCED SENESCENT CELLS FOR CANCER TREATMENT | THE UNIVERSITY OF CHICAGO (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-2427431-B1 | NOVEL INDICATOR PLATFORM | BIOSYNTH AG (CH) | 2013-05-01 | — | — | EP | disclosed |
| EP-2256103-A1 | Novel indicator platform | Biosynth AG (CH) | 2010-12-01 | — | — | EP | disclosed |
| US-6902929-B1 | Retroviral vectors, methods for their preparation and their use for gene transfer into CD4-positive cells | BUNDESREPUBLIK DEUTSCHLAND LAST REPRESENTED BY THE PRESIDENT OF THE PAUL-EHRLICH-INSTITUTS (DE) | 2005-06-07 | — | — | US | disclosed |